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Abstract 
Intercurrent events (ICEs) and missing values are inevitable in clinical trials of any size and duration, 
making it difficult to assess the treatment effect for all patients in randomized clinical trials. Defining the 
appropriate estimand that is relevant to the clinical research question is the first step in analyzing data. 
The tripartite estimands, which evaluate the treatment differences in the proportion of patients with ICEs 
due to adverse events, the proportion of patients with ICEs due to lack of efficacy, and the primary 
efficacy outcome for those who can adhere to study treatment under the causal inference framework, are 
of interest to many stakeholders in understanding the totality of treatment effects. In this manuscript, we 
discuss the details of how to estimate tripartite estimands based on a causal inference framework and how 
to interpret tripartite estimates through a phase 3 clinical study evaluating a basal insulin treatment for 
patients with type 1 diabetes. 
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1. Introduction 
From the passage of the landmark Kefauver Harris Amendment of the United States Federal Food, Drug 
and Cosmetic Act [1] to the present day, increasing rigor has been required in the statistical design, 
analysis, and interpretation of adequate and well-controlled trials. ICH-E9: Statistical Principles for 
Clinical Trials [2] provides guidance on statistical principles in study design and data analysis. More 
recently, the issuance of the National Research Council report on The Prevention and Treatment of 
Missing Data in Clinical Trials [3] explicitly highlights the notion of the estimand. As noted in that 
treatise, “Estimation of the primary (causal) estimand, with an appropriate estimate of uncertainty, is the 
main goal of a clinical trial”. ICH E9 (R1), a recent addendum to ICH-E9, discusses estimands in greater 
detail, especially the role of intercurrent events (ICEs) in defining estimands [4]. ICH E9 (R1) states, 
“Intercurrent events are events occurring after treatment initiation that affect either the interpretation or 
the existence of the measurements associated with the clinical question of interest”. ICH E9 (R1) provides 
5 types of strategies to handle ICEs in defining the estimand: treatment policy strategies, hypothetical 
strategies, composite variable strategies, while on treatment strategies, and principal stratum strategies. 
All strategies except the principal stratum strategies intend to define an estimand for all patients. In 
addition, there are limited discussions on the estimands related to safety, especially for the estimands 
related to ICEs themselves.  
As the assessment of any new treatment is always a balance between treatment effects related to both 
benefit and risk, Akacha, Bretz and Ruberg [5] have proposed the tripartite approach – a set of three 
estimands that they argue are meaningful not only to patients, prescribers, and payers, but also sponsors 
and regulators. Their tripartite estimands are: 
1. Probability of patients discontinuing study treatment due to adverse events (AE) 
2. Probability of patients discontinuing study treatment due to lack of efficacy (LoE) 
3. The treatment effect in patients who can adhere to treatment 
For Estimand 3, the adherence status is a post-randomization variable that may depend on the assigned 
treatment and, consequently, the adherence sets for the 2 treatment groups may not be comparable. The 
causal inference framework is required to define the estimand and construct a corresponding estimator. 
Qu et al. propose a theoretical framework for adherence causal estimators (ACEs) based on the causal-
inference framework for the estimands of Estimand 3 [6], but they do not provide details on the 
implementation of tripartite estimands.  
In this article, we will clarify the tripartite estimands using the terminology in ICH E9 (R1). Specifically, 
we define the Estimands 1 and 2 for the proportion of patients with their first ICEs due to AE and LoE 
(not just treatment discontinuation) and define Estimand 3 using the principal stratum strategies in the 
causal inference framework [7]. We will then provide details on how to implement the tripartite estimands 
in clinical trials through retrospective analyses of a phase 3 study. The article is organized in the 
following way. Section 2 will discuss the statistical methods including the refinement of the tripartite 
estimands and review the statistical method for the estimation of Estimand 3 as presented by Qu et al. [6]. 
Section 3 will cover information relevant to the clinical case study, including the data and specific details 
for our implementation of the tripartite analysis, and will present the analysis results. Finally, Section 4 
will discuss our learnings, additional considerations, and potential for further research. For the purposes 
of this manuscript, we will use the term “treatment” to cover drugs, biologics, or any well-defined 
intervention and will focus on the clinical trial or development program for such treatments, most notably 
confirmatory trials that usually constitute phase 3 of clinical development.  
2. Methods 
For a treatment that has a prolonged effect on a primary efficacy measure or is a disease-modifying agent, 
even data collected after ICEs retain some measure of the randomized treatment effect even with the 
discontinuation of that randomized treatment or in the presence of rescue medication and can be used to 
assess the causal effect of the treatment (e.g., disease-modifying antirheumatic drugs or DMARDs). For a 
treatment that has a more immediate offset of effect on a primary response variable (e.g., a treatment that 
temporarily ameliorates symptoms), data collected after the cessation of treatment may be additionally 
confounded by the ICEs, and thus may not be appropriate to be directly used in assessing the causal effect 
of that treatment. In this article, we address the latter situation. 
To define the tripartite estimands, we first introduce the notations of variables of interest and potential 
outcomes. For intercurrent events, we let 𝐷max be the designed duration of treatment for the study, 𝐷𝐴𝐸 
denote the time to the occurrence of an ICE due to AE, 𝐷𝐿𝑜𝐸 denote the time to the occurrence of an ICE 
due to LoE, and 𝐷𝐴 denote the time to the occurrence of an ICE due to administrative reasons. 
Additionally, let 𝑌 denote the primary outcome, 𝑍 be the intermediate outcome on which the intercurrent 
events and/or 𝑌 may depend, 𝑇 be the treatment indicator (0 for the reference treatment and 1 for the 
experimental treatment), and 𝐴 be the adherence indicator (0 for not being adherent [i.e., with ICEs] and 1 
for being adherent [i.e., without ICEs]). Then, the adherence indicator is given by 
𝐴 = 𝐼(𝐷𝐴𝐸 > 𝐷max) ⋅ 𝐼(𝐷𝐿𝑜𝐸 > 𝐷max) ⋅ 𝐼(𝐷𝐴 > 𝐷max). 
For any variable, the potential outcome under a treatment 𝑇 is denoted by “(𝑇)” following the variable. 
For example, 𝑌(1) denotes the potential outcome under the experimental treatment. 
Incorporating the intercurrent events terminology in ICH E9 (R1) and the principal stratum strategies [7-
14] for the estimand, a set of tripartite estimands is defined as: 
1. For all patients, the treatment difference in the probability of patients with the first ICE due to 
adverse events (AE)  
2. For all patients, the treatment difference in the probability of patients with the first ICE due to 
lack of efficacy (LoE) 
3. For patients who are in a principal stratum defined by treatment adherence, the difference in the 
primary efficacy outcome. 
The analysis variable (𝐼𝐴𝐸) for the first estimand is the occurrence (yes or no) of the first ICE due to AE, 
and the analysis variable (𝐼𝐿𝑜𝐸) for the second estimand is the occurrence (yes or no) of the first ICE due 
to LoE. Then, the variables 𝐼𝐴𝐸 and 𝐼𝐿𝑜𝐸 can be defined as 
𝐼𝐴𝐸 = {
1 𝐷𝐴𝐸 ≤ 𝐷max and 𝐷𝐴𝐸 ≤ 𝐷𝐿𝑜𝐸  and 𝐷𝐴𝐸 ≤ 𝐷𝐴
0 Otherwise
                                         (1) 
and 
𝐼𝐿𝑜𝐸 = {
1 𝐷𝐿𝑜𝐸 ≤ 𝐷max and 𝐷𝐿𝑜𝐸 ≤ 𝐷𝐴𝐸  and 𝐷𝐿𝑜𝐸 ≤ 𝐷𝐴
0 Otherwise
.                                    (2) 
Based on the definitions in (1) and (2), the sets {𝐼𝐴𝐸 = 1} and {𝐼𝐿𝑜𝐸 = 1} are not exclusive. A patient may 
discontinue a treatment due to both AE and LoE when 𝐷𝐴𝐸 = 𝐷𝐿𝑜𝐸. The first and second estimands can 
be mathematically expressed as 
𝑒1 = 𝐸[𝐼𝐴𝐸(1) − 𝐼𝐴𝐸(0)]                                                                    (3) 
and 
𝑒2 = 𝐸[𝐼𝐿𝑜𝐸(1) − 𝐼𝐿𝑜𝐸(0)],                                                                (4) 
respectively. Based on the definitions in (1) and (2), 𝐼𝐴𝐸 and 𝐼𝐿𝑜𝐸 are observed for every patient. 
Therefore, estimation of the first 2 estimands is very straightforward. Note those with ICEs due to 
administrative reasons (e.g., moving to a new house, inconvenience due to job changes) are independent 
of treatment and the primary outcome given baseline covariates. Therefore, the baseline characteristics for 
patients with ICEs due to administrative reasons should be balanced between treatment, and an estimand 
for patients who discontinue due to administrative reasons does not seem relevant and is not pursued in 
the tripartite approach. Note ICEs due to administrative reasons may depend on baseline covariates, but it 
will not create imbalance between treatment groups. 
For Estimand 3, the adherence principal stratum can be defined as adhering to one of the randomized 
treatments or both randomized treatments, depending on the clinical population of interest.  
A general form of the third estimand can be described as 
𝑒3 = 𝐸{𝑌(1) − 𝑌(0)|𝑆},                                                                (5) 
where S can be any principal stratum based on adherence. The estimation of the treatment effect for such 
a principal stratum was first proposed by Frangakis and Rubin [8], and there have been subsequent 
overviews and discussions of estimation for principal stratum [10, 12, 15]. Generally, there are 4 
approaches in estimating 𝑒3 in (5):  
• Methods based on monotonicity assumption [9, 13, 16-19] 
• Methods that estimate the boundary, assume some sensitivity parameter(s), or use the Bayesian 
method to pose restriction on the sensitivity parameters [13, 14, 20, 21] 
• Methods based on estimating the principal score (the probability belonging to a principal stratum) 
based on baseline covariates [18, 22, 23] 
• Methods based on the estimation of potential outcome and/or principal score via baseline 
covariates and potential post-baseline intermediate measurements [7, 11] 
All the above methods require relatively strong assumptions. The monotonicity assumption, such as 
𝐴(1) ≥ 𝐴(0) or 𝐴(1) ≤ 𝐴(0), is unreasonable because it assumes a deterministic inequality between 2 
random variables. The adherence status 𝐴(𝑡) is a random variable that cannot be observed when 𝑡 is not 
equal to the assigned treatment 𝑇 in parallel studies. For a given study population, if we repeat the clinical 
trial (random treatment assignment and subsequent follow-up) many times, the set of adherers for each 
treatment will likely be different for each realization of the repeated clinical trial. This is fundamentally 
different from all randomized patients, which are fixed once the enrollment completes. For convenience, 
we will still use “population” or “stratum” to describe such a random set of adherent patients, but in all 
statistical derivations, we treat 𝐴 as a random variable.  
Methods for estimating the boundary of the estimand on a principal stratum and methods depending on 
sensitivity parameters can only be used for sensitivity analysis because they either cannot provide a 
consistent estimator, or the sensitivity parameter cannot be objectively estimated. Methods of estimation 
using a principal score based on baseline covariates are also unlikely to be sufficient because baseline 
covariates may not always predict the final clinical outcome or principal stratum status. Methods 
estimating the potential outcome or principal stratum via both baseline covariates and post-baseline 
intermediate outcomes, in spite of some strong assumptions, seem more reasonable than the other three 
approaches. 
We consider 3 principal strata (populations) that are of interest in general: 
• 𝑆∗∗ = {𝐴(0) ∈ {0,1}, 𝐴(1) ∈ {0,1}}, which is the population of all patients 
• 𝑆∗+ = {𝐴(1) = 1}, which is the principal stratum for patients that are adherent to treatment 𝑇 =
1, 𝑟𝑒𝑔𝑎𝑟𝑑𝑙𝑒𝑠𝑠 𝑜𝑓 𝑎𝑑ℎ𝑒𝑟𝑒𝑛𝑐𝑒 𝑡𝑜 𝑇 = 0 
• 𝑆++ = { 𝐴(0) = 1, 𝐴(1) = 1}, which is the principal stratum for patients that are adherent to both 
treatments 
The population 𝑆∗∗ is not of interest in this tripartite approach but, for comparison, the treatment effect 
will be estimated for this population in the example in Section 3. The choices of 𝑆∗+ and 𝑆++ are based on 
the arguments presented by Qu et al [6] and Permutt [10]. For placebo-controlled studies, 𝑆∗+ is clinically 
meaningful as trial stakeholders are more interested in the population of patients who can adhere to an 
investigational treatment, regardless of adherence to placebo. For active controlled trials, the target 
population for the estimand of interest is 𝑆++. In this situation, one can imagine that a physician is making 
a choice between treatments: the selection of which treatment will produce a more efficacious outcome 
should be based on the principal stratum of patients who could adhere to both treatments. Of course, if it 
is known that one treatment also increases the likelihood of adherence, such trade-offs need to be 
considered when making prescribing decisions. 
In this article, we applied ACEs for the treatment difference for those who can adhere to one treatment or 
both treatments based on a causal inference framework [6]. These estimators are consistent for the 
treatment effect in the adherent strata of interest under some assumptions, and simulations demonstrated 
that the ACEs provide consistent estimates of the treatment difference for sample sizes that are typical for 
clinical trials. As the methods are complex and have been previously described [6], here we only provide 
a high-level description of the methods. The following assumptions have been posed for the validity of 
the ACEs:  
A1:  𝑌 = 𝑌(1)𝑇 + 𝑌(0)(1 − 𝑇) 
A2:  𝑍 = 𝑍(1)𝑇 + 𝑍(0)(1 − 𝑇) 
A3:  𝐴 = 𝐴(1)𝑇 + 𝐴(0)(1 − 𝑇) 
A4:  𝑇 ⊥ {𝑌(1), 𝐴(1), 𝑍(1), 𝑌(0), 𝐴(0), 𝑍(0)}|𝑋 
A5:  𝐴{𝑖} ⊥ {𝑌(1), 𝑌(0), 𝑍(1 − 𝑖)}|{𝑋, 𝑍(𝑖)}, ∀ 𝑖 = 0,1 
A6:  𝑌(𝑖) ⊥ 𝑍(1 − 𝑖)|{𝑋, 𝑍(𝑖)}, ∀ 𝑖 = 0,1 
A7:  𝑍(0) ⊥ 𝑍(1)|𝑋 
The sign “⊥” denotes “statistically independent”. Assumptions A1-A3 are the stable unit treatment value 
assumptions, i.e., the hypothetical outcome is the same as the observed outcome under the same 
treatment, which are reasonable and standard in causal inference approaches. Assumption A4 is the 
ignorable treatment assignment assumption [12].  Assumption A5 is the ignorable adherence assumption, 
which means adherence only depends on observed values. This means that the probability of ICEs can be 
modelled through the observed data (e.g., occurrence of an AE or deterioration of efficacy) during the 
clinical trial. We believe this is reasonable since patients are likely to continue their study treatment for 
the duration of a trial unless they are experiencing some unsatisfactory response, which we can observe or 
deduce from observed data, or for some administrative reason completely unrelated to treatment or 
baseline characteristics. Assumption A6 means, conditional on the baseline values and the intermediate 
outcome under one treatment, the outcome for this treatment is independent of the potential intermediate 
outcome in the other treatment. Assumption A7 assumes the potential intermediate outcomes under the 2 
treatments are independent given baseline covariates. The dependencies between treatment, the baseline 
covariate, the intermediate outcome, the primary outcome, and the adherence are illustrated by the causal 
diagram in Figure 1. 
 
Figure 1: Causal diagram showing the dependencies between treatment (𝑇), baseline covariate (𝑋), post-baseline 
intermediate variable (𝑍), adherence (𝐴), and outcome (𝑌). 
Under Assumptions A1-A7, a consistent estimator for the treatment difference for stratum 𝑆∗+ is given by 
1
𝑛11
∑ 𝑌𝑗
𝑗∈{𝑇𝑗=1,𝐴𝑗=1}
−
1
𝑛11
∑ ?̂?0(𝑋𝑗)
𝑗∈{𝑇𝑗=1,𝐴𝑗=1}
,                                               (1)  
where 𝑗 is the subject index, 𝑛11 is the number of patients who are adherent to the treatment when they 
take the experimental treatment, and ?̂?𝑡(𝑋𝑗) is the estimated potential response for subject 𝑗 if taking 
treatment 𝑇 = 𝑡, (𝑡 = 0,1). The function 𝜙0 is estimated using the data in the reference treatment group 
by first building a regression model of Y on X and Z, and then conditioning on X. Then, the potential 
outcome under the reference treatment for subjects assigned to the experimental treatment, also called 
“virtual twin”, is estimated and denoted as ?̂?0(𝑋𝑗). Finally, the treatment difference for 𝑆∗+ can be 
estimated by taking the average of the difference between the observed outcome for the adherent patients 
on the experimental treatment and the potential outcome under the experimental treatment for those same 
patients in the reference treatment group. 
A consistent estimator for the treatment difference for stratum 𝑆++ is given by 
∑ ?̂?1(𝑋𝑗)𝑗∈{𝑇𝑗=0,𝐴𝑗=1}
∑ ℎ̂1(𝑋𝑗)𝑗∈{𝑇𝑗=0,𝐴𝑗=1}
−
∑ ?̂?0(𝑋𝑗)𝑗∈{𝑇𝑗=1,𝐴𝑗=1}
∑ ℎ̂0(𝑋𝑗)𝑗∈{𝑇𝑗=1,𝐴𝑗=1}
,                                                  (2) 
where ?̂?𝑡(𝑋𝑗) is the expected value of the product of the probability of adherence and the response of Y, 
conditional on 𝑋𝑗 if patient j takes treatment 𝑇 = 𝑡, and ℎ̂𝑡(𝑋𝑗) is the expected probability of adherence, 
conditional on 𝑋𝑗 if patient j takes treatment 𝑇 = 𝑡. For the ACE estimator in (2), in addition to the 
assumption for the ACE estimator in (1), we also assume the principal score (i.e., the probability of 
treatment adherence) is a function of baseline covariates (𝑋) and intermediate outcome (𝑍). The idea is 
that the estimator for the mean response for treatment 𝑇 = 𝑡 on S++ is calculated using the weighted 
average of the potential outcome on the alternative treatment (i.e., 𝑇 = 1 − 𝑡) by the probability of 
adherence to the alternative treatment (𝑇 = 1 − 𝑡). The probability of adherence to the alternative 
treatment can be estimated using the baseline covariates and the potential intermediate outcome under the 
alternative treatment, which is estimated in a similar fashion as ?̂?𝑡(𝑋𝑗). The ?̂?𝑡(𝑋𝑗) is the expected value 
of the product of this probability of adherence to the alternative treatment and ?̂?𝑡(𝑋𝑗), conditional on X. 
Again, the details for the construction of ?̂?𝑡 , ?̂?𝑡, and ℎ̂𝑡 have previously been described in detail [6]. 
Note the principal stratum of patients who would adhere to both treatments (𝑆++) cannot be observed. 
One estimator for the proportion of patients that would adhere to both treatments (𝑝++) is 
?̂?
++
=
∑ ℎ̂0(𝑋𝑗)𝑗∈{𝑇𝑗=1,𝐴𝑗=1} + ∑ ℎ̂1(𝑋𝑗)𝑗∈{𝑇𝑗=0,𝐴𝑗=1}
𝑛1 + 𝑛0
.                                              (3) 
3. Application 
3.1. The study and data 
The data used in this article are based on the IMAGINE-3 Study: a 52-week, multi-center, phase 3 study 
of patients with type 1 diabetes mellitus. This was a parallel, double-blind study with randomization of 
qualified patients to basal insulin lispro (BIL) versus insulin glargine (GL). In this trial, 1114 adults with 
type 1 diabetes were randomized to BIL and GL in a 3:2 ratio (664 in BIL: 450 in GL), stratified by 
baseline hemoglobin A1c (HbA1c) (≤8.5%, >8.5%), baseline low-density lipoprotein cholesterol (LDL-
C) (<100 mg/dL [2.6 mmol/L], ≥100 mg/dL), and prior basal insulin therapy (GL/insulin detemir/other 
basal insulin). In the first 12 weeks of the titration period, BIL or GL dose was adjusted weekly. Patients 
then entered the maintenance period (Weeks 12 to 52). During the study, patients were not allowed to 
take additional anti-diabetes medication unless they discontinued the randomized study treatment. 
Therefore, we consider treatment discontinuation as the only ICE for this study. The stated primary 
objective of the clinical trial was to demonstrate superiority of BIL to GL on HbA1c after 52 weeks of 
treatment.  The study was conducted in accordance with the International Conference on Harmonization 
Guidelines for Good Clinical Practice and the Declaration of Helsinki. All patients signed an informed 
consent document, and the protocols and consent documents were approved by local ethical review 
boards prior to study initiation. This study was registered at clinicaltrials.gov as NCT01454284 and 
details of the study report have been published [24]. 
This post hoc analysis was conducted on all randomized patients who took at least one dose of the study 
drug (n=1112). One patient in each treatment arm did not take any study drug after randomization. Per the 
study design and data collection instruments, patient disposition was classified into 7 categories: AE, 
death, lost to follow-up, protocol violation, withdrawal by subject, physician decision, or sponsor 
decision. Detailed AE reports and some free-text comments from investigators suggested that the above 7 
categories did not always reflect the real reason for discontinuation. For example, some patients who were 
discontinued due to LoE based on written comments in the case report form and laboratory measures of 
blood glucose were recorded as “physician decision.” Furthermore, some patients who were discontinued 
due to a protocol specified AE were recorded as “sponsor decision.” Therefore, using all data available, 
we re-assessed the treatment discontinuations to define the variables (𝐼𝐴𝐸 and 𝐼𝐿𝑜𝐸) related to the first 2 
estimands. Based on the definitions of 𝐼𝐴𝐸 and 𝐼𝐿𝑜𝐸, it is possible that a patient may have 2 simultaneous 
ICEs: one due to AE and one due to LoE.  
In order to accurately define 𝐼𝐴𝐸 and 𝐼𝐿𝑜𝐸, we manually reviewed data for each individual patient who 
discontinued the study or permanently discontinued the study treatment. The data included investigator 
provided reasons for discontinuation, investigators’ comments on the discontinuation, efficacy data 
(HbA1c and glucose at baseline and prior to discontinuation), and safety data including adverse events 
and laboratory data (e.g., lipid panel and liver enzymes collected within 90 days before discontinuation). 
A conservative approach was implemented to classify early discontinued patients into the ICE category of 
“due to AE” if there were any recorded data or comments suggesting such was the case. Specifically, a 
patient’s discontinuation was classified as an ICE due to AE if the investigator indicated it was “due to 
AE”, or there were obvious safety issues such as the emergence of adverse events and/or abnormal 
laboratory data which could lead to discontinuation. A patient’s discontinuation was classified as an ICE 
due to LoE if his or her HbA1c or glucose values at discontinuation were believed to have had no 
meaningful improvement from baseline values. A patient’s discontinuation was classified as an ICE due 
to administration if there was no obvious evidence showing the discontinuation was due to an AE or LoE. 
Figure 2 summarizes the ICE classification criteria.  
 Discontinuation Reason in 
Database 
  
  
ICE Classification  Classification Criteria 
• Adverse Event 
• Death 
      
 
Due to AE 
With AE or abnormal lab that 
could lead to discontinuation 
• Lost to Follow-up 
• Protocol Violation 
• Withdrawal by Subject 
• Physician Decision 
• Sponsor Decision 
      
 
Due to LoE 
No obvious improvement in 
HbA1c or glucose at 
discontinuation as compared 
to baseline values 
      
  Due to administration 
No clear safety or lack of 
efficacy reason leading to 
discontinuation 
      
Figure 2. ICE classification criteria 
 
3.2. Proportion of patients who had the first ICE due to AE and LoE (Estimands 1 and 2) 
Among the 1114 randomized patients, 1112 patients (663 in BIL, 449 in GL) took at least one dose of 
study drug. Baseline characteristics for all randomized patients were balanced between the two treatment 
groups as expected [24]. During the 52 weeks of treatment, 235 patients experienced at least one ICE 
before completing the 52-week treatment period: 94 (8.5%) patients had the first ICE due to AE, 29 
(2.6%) patients had the first ICE due to LoE, 120 (10.8%) patients had the first ICE due to administrative 
reasons, and 877 (78.9%) patients adhered to the treatment (Table 1). Significantly more patients had the 
first ICE due to AE in the BIL treatment group compared to GL (10.6% vs 5.3%; p=0.002). The disparity 
of ICEs due to AE was primarily due to injection site reactions [24]. The percentages of patients who had 
the first ICE due to LoE were similar between BIL and GL (2.7% vs 2.4%; p=0.850). The percentages of 
patients who had the first ICE due to administrative reasons were also quite similar between treatment 
groups (10.6% vs 11.1% for BIL vs GL, respectively; p=0.768). The cumulative incidences of the first 
ICE due to each reason over time are presented in Figures 3(a), 3(b), and 3(c).  
For ICEs due to LoE, an important question from patients is “How long do I have to wait to know if I will 
respond or not to treatment?” Figure 3(d) summarizes the proportion of the first ICE due to LoE by time 
interval for each treatment. Among those who had the first ICE due to LoE, approximately half occurred 
during the first 3 months, approximately two thirds during the first 6 months, and the remaining third 
occurred over the last 6 months of the trial. 
Table 1. Summary and Comparison of Proportion of Patients with Categories of First ICEs 
Disposition 
GL 
(N=449) 
n (%) 
BIL 
(N=663) 
n (%) 
Difference (%, 
95% CI)  
(BIL vs GL) 
 
P-value 
All Patients with ICEs, n (%)† 81 (18.0) 154 (23.2) 5.2 (0.4, 10.0) 0.043 
    First ICE due to AEs, n (%) 24 (5.3) 70 (10.6) 5.2 (2.1, 8.3) 0.002 
    First ICE due to LoE, n (%) 11 (2.4) 18 (2.7) 0.3 (-1.6, 2.2) 0.850 
    First ICE due to Administrative Reasons, n (%) 50 (11.1) 70 (10.6) -0.6 (-4.2, 3.2) 0.768 
Abbreviations: AE, adverse event; BIL, basal insulin lispro; CI, confidence interval; GL, insulin glargine; 
ICE, intercurrent event; LoE, lack of efficacy.  
†Eight patients had concurrent first ICE due to AE and ICE due to LoE 
 
 
 
(a) Cumulative Incidence of the first ICE due to AE 
  
 
 
(b) Cumulative incidence to the first ICE due to LoE 
  
 
 
(c) Cumulative incidence for the first ICE due to administration 
 
 
 
(d) The percentage of patients with the first ICE due to LoE by 
time period  
Figure 3. Cumulative incidence of the first ICE (panels (a), (b), and (c)) and a histogram of time of the 
first ICE due to LoE (panel (d)). 
3.3. Baseline characteristics for adherers and non-adherers 
There are two other important comparisons of baseline characteristics in this analysis using the tripartite 
estimand approach, especially related to Estimand 3: 
1) A comparison of those patients who discontinued the study treatment with those patients who 
adhered to the study treatment in order to understand if the discontinued patients might be 
different from the adherers. This can provide insight into how the adherent stratum might differ 
from the all randomized patient population; 
2) For those who adhered to the assigned treatment for the duration of the study, the baseline 
characteristics for adherers between BIL and GL were compared to explore potential differences 
between the 2 adherers sets. While this gives insight into the comparability of the study 
treatments for the observed group of adherers, it is recognized that there may be unmeasured 
baseline covariates that are imbalanced since these patients are no longer randomized groups. 
Table A.1 in the Appendix summarizes the demographic and baseline characteristics for the 4 groups (3 
categories of first ICEs and adherers). Statistical comparisons were conducted between adherers and non-
adherers. Compared to adherers, non-adherers were slightly more likely to be female, younger with lower 
body weight, have higher baseline HbA1c and triglyceride values, and lower total bilirubin. Furthermore, 
the non-adherers were more likely to be current smokers and to use statins, and less likely to be from 
Europe. The predictability of adherence using these baseline variables with multiplicity adjustment was 
also evaluated using a gradient boosting model [20]. Results showed the most influential baseline 
covariate on adherence was the age of the patient with a relative importance of 31% (adjusted p-value = 
0.182) (Figure A.1). Thus, there were some differences between the adherers and non-adherers, but the 
differences did not seem to be dramatic.  
Table A.2 in the Appendix summarizes and compares the demographics and baseline characteristics of 
the adherers by their respective treatment groups. Demographic and baseline characteristics were very 
similar for patients who adhered to the study treatment between the BIL and GL groups, with the only 
possible exception being estimated glomerular filtration rate (eGFR) (p=0.09). This slight difference was 
viewed as having minimal, if any, clinical significance in assessing the HbA1c response. In addition, all 
these baseline characteristics were included in a subgroup identification analysis to evaluate potential 
baseline variables that could predict differential adherence status between treatment groups with 
multiplicity-adjusted p-values [25]. The results showed that none of these measures were predictive of 
who would discontinue study treatment across treatment groups (baseline eGFR had the smallest 
multiplicity adjusted p-value of 0.242). Thus, despite being self-selected groups of patients, those patients 
who adhered to their GL and BIL treatment assignment were very similar with respect to measured 
baseline characteristics. 
3.4 Efficacy for adherers (Estimand 3) 
There were 76.8% and 82.0% of patients who adhered to BIL and GL during the 52 weeks of treatment, 
respectively. As mentioned previously, direct comparison of the efficacy for the adherers between the 2 
treatments was not recommended because it does not estimate any causal estimand.  
To use the methods proposed by Qu et al to model the probability of adherence and predict the post-
baseline outcomes, we consider the following baseline covariates (X) that could potentially impact 
treatment adherence: age, gender, HbA1c, LDL-C, triglyceride (TG), fasting serum glucose (FSG), and 
alanine aminotransferase (ALT). The study also collected HbA1c, LDL-C, TG, FSG, and ALT at Week 
12 and Week 26, and injection site reaction adverse events (a binary variable) that occurred between 
randomization and Week 12 and between Week 12 and Week 26. Those 6 post-baseline variables were 
considered in intermediate covariates 𝒁1 for Week 12 and 𝒁2 for Week 26, respectively. The probability 
of adherence was estimated using a multiplicative probability model [6].  
Estimates of the treatment effect for the two principal strata of interest (𝑆∗+ and 𝑆++) are provided in 
Table 2. In Table 2, we also present other commonly used methods: 
• Naïve adherers analysis. This analysis makes a simple comparison of treatment effect on the 
adherers in one treatment group to the adherers in another group without considering the potential 
imbalance for the adherers between the two treatment groups. Using our previous notation, this 
estimator tries to estimate  
𝐸{𝑌(1)|𝐴(1) = 1) − 𝐸{𝑌(0)|𝐴(0) = 1}, 
which apparently does not have a clear clinical meaning since it conditions on 2 different patient 
strata. 
• Mixed model with repeated measures (MMRM) analysis using all observed data prior to the 
occurrence of ICEs. This analysis estimates the treatment difference in HbA1c at 52 weeks for all 
randomized patients, assuming all patients would adhere to the treatment without ICEs, i.e.,  
𝑒4 = 𝐸{𝑌(1) − 𝑌(0)|𝑆∗∗}, 
which is an estimand based on the hypothetical strategy. This analysis assumes the missing data 
(either unobserved or censored by ICEs) are random.  
• MMRM analysis with jump to reference (J2R) multiple imputations [26]. In this analysis, which 
includes the observed data prior to the occurrence of ICEs, the missing data (either unobserved or 
censored by ICEs) in the experimental treatment group were first imputed using the observed data 
in the reference arm, and then the MMRM model is applied to the imputed dataset. This analysis 
also estimates the estimand 𝑒4, but assumes missing data are not missing at random.  
Table 2. Estimates for various estimands for HbA1c at 52 weeks and the treatment difference 
Method 
GL 
(LS mean ± SE) 
BIL 
(LS mean ± SE) 
Treatment difference for 
BIL vs GL (95% 
confidence interval) 
Naïve adherers estimator 7.57 ± 0.04 7.34 ± 0.03 -0.23 (-0.33, -0.14) 
ACE on 𝑆∗+ 7.59 ± 0.05 7.34 ± 0.04 -0.25 (-0.35, -0.15) 
ACE on 𝑆++ 7.55 ± 0.05 7.31 ± 0.05 -0.24 (-0.37, -0.10) 
MMRM on 𝑆∗∗ 7.61 ± 0.04 7.38 ± 0.03 -0.22 (-0.32, -0.12) 
MMRM after J2R 
imputations on 𝑆∗∗ 
7.62 ± 0.04 7.41 ± 0.03 -0.21 (-0.30, -0.11) 
Abbreviations: ACE, adherers causal estimator; BIL, basal insulin lispro; GL, insulin glargine; J2R, jump 
to reference; LS, least squares; MMRM, mixed model with repeated measures; SE, standard error.  
All estimates had similar results with the difference between estimates not exceeding 0.04%. It is not 
surprising to see the estimate for the naïve adherer set was similar to the estimate for stratum 𝑆++ and 𝑆∗+, 
as the baseline characteristics for the adherers between the GL and BIL treatment groups were similar. 
The estimates for stratum  𝑆++ were fairly similar to the estimates for the MMRM analyses with and 
without imputations. However, the ACEs are estimators based on principal stratification and they are 
fundamentally different from other estimators. The similarity between various estimates for different 
estimands is not surprising, as the ICEs due to AE (mostly injection reactions) or administrative reasons 
were not considered to be related to the efficacy based on the mechanism of action of both insulin 
treatments. 
3.5. Graphical display of the tripartite estimands results 
With the analyses in Sections 3.2 and 3.4, the tripartite estimands can be displayed in Figure 4. In the GL 
treatment arm, 24 (5.3%) patients discontinued study medication due to AE with a mean treatment 
exposure of 23.1 weeks, and 11 (2.4%) patients discontinued study medication due to LoE with a mean 
treatment exposure of 16.5 weeks. In the BIL treatment arm, 70 (10.6%) patients discontinued the study 
medication due to AE with a mean treatment duration of 12.3 weeks, and 18 (2.7%) patients discontinued 
study medication due to LoE with a mean treatment exposure of 19.6 weeks. For those who adhered to the 
BIL treatment (i.e., 𝑆∗+), the treatment difference (BIL vs. GL) was -0.25% (95% CI: -0.35%, -0.15%). 
The expected proportion of patients that would adhere to both treatments (𝑆++) was estimated to 61.9% 
and the treatment difference for these (potential) patients was -0.24% (95% CI: -0.37%, -0.10 %). 
Regardless of whether the tripartite approach is used in the analysis or any form of ACE is used for 
estimation, the graphic presentation like Figure 4 provides a useful summary of for treatment 
discontinuations in a clinical study. 
Figure 4. Visual display of the tripartite estimands. Abbreviations: AE, adverse events; BIL, basal insulin peglispro; 
CI, confidence interval; GL, basal insulin glargine; LoE, lack of efficacy; 𝑆∗+, a subset of patients those who 
adhered to the BIL treatment; 𝑆++, a subset of patients those who would adhere to both treatments; SE, standard 
error. 
4. Summary and Discussion 
ICH E9 (R1) provides guidance on defining estimands, with a major focus on 5 specific strategies. All 
strategies except for the principal stratum approach focus on the treatment effect in all randomized 
patients. In regulatory interactions and key medical publications, there are almost no examples of using 
the principal stratum estimands for the primary analysis, with intent-to-treat (ITT) being the default 
strategy, enhanced by its recommendation in ICH-E9. While estimation for all randomized patients has 
been used for decision-making, we believe there are many situations when the estimands for principal 
stratum, especially based on the treatment adherence status, may be of interest or may even be considered 
for the primary estimands.   
The most important qualifier for any estimand is that it should be first and foremost clinically meaningful. 
If the statistical design of clinical trials and the ensuing analysis is not aligned with what is clinically 
meaningful – both to prescribers and patients – then even the finest statistical science is at best misguided 
and at worst self-serving. Undoubtedly, the interplay between what is clinically meaningful and what is 
statistically estimable requires thoughtful collaboration between clinicians, regulators, and statisticians [4, 
27]. ICH E9 (R1) rightly states, “It should be agreed that reliable estimation is possible before the choice 
of estimand is finalized.” Of course, “reliable estimation” is a subjective term; however, paraphrasing 
John Tukey, an approximate answer to the right question is much more desirable than a precise answer to 
the wrong question [28]. As ICEs and missing values exist, some assumptions, which often cannot be 
verified, are almost always required to derive consistent estimators for the estimand.   
In some sense, an estimand based on the all randomized patient population is an unconditional estimand; 
that is, a description of what happens on average to everyone, a mixture of patients who adhere to their 
randomized treatment and those who do not adhere. It answers the question, “What is the expected 
treatment effect before the patient starts the treatment?” or “What is the expected treatment effect based 
on initiation of treatment?”. In the tripartite approach, Estimand 3 is a conditional estimand which 
provides an answer to an important question, “What is the expected treatment effect in patients who can 
adhere to their treatment?” The formulation of the paper is related to the estimand in the principal stratum 
of patients who can adhere to treatment for the duration of the study. We suspect that most patients 
initially intend to adhere to a newly prescribed medication and want to know the expected outcome under 
that condition, even if they know or suspect there is a chance that they cannot adhere for one reason or 
another.  
Of course, at the initiation of a new treatment, no one knows how an individual patient will respond. The 
question is, what should a physician communicate to the patient, or what should the sponsor/regulator 
communicate to the physician, about the expected response to treatment. We perceive the estimates 
provided by the tripartite estimands, when considered collectively, are more nuanced and informative for 
making benefit-risk decisions about initiating a new treatment. Furthermore, if they are indeed a more 
complete description of the treatment effect for the primary customer and consumer of the treatment, then 
perhaps they should also play a central role in regulatory decision-making and labeling. 
A treatment can have an effect on those patients who take it, but also has an effect on which patients can 
take it in the first place. A complete description of the treatment effect includes both. While ICH E9 (R1) 
mostly discusses the role of ICEs in defining estimands for the primary outcome, it also mentions the 
value of defining estimands for ICEs themselves (see for example Section A.3.4). The tripartite estimands 
define 2 estimands for ICEs: the treatment differences in the proportion of patients with the first ICE due 
to AE and the proportion of patients with the first ICE due to LoE. This provides a more holistic approach 
in assessing efficacy and safety for decision-making by all stakeholders. This exercise also illuminated us 
on the ambiguities and potential deficiencies in capturing the reasons for discontinuation of study 
medication. We believe that the industry would benefit from redesign of standard case report forms for 
treatment discontinuation that are more explicit in capturing the reasons for discontinuation study 
medication, especially if it is for adverse events or lack of efficacy.  
We applied the causal tripartite estimands retrospectively to a phase 3 clinical trial. For Estimand 3, the 
treatment difference for adherers, we used the recently developed ACEs with assumptions that we believe 
to be more reasonable than the monotonicity assumption used by most causal-inference estimation for 
adherers. We understand the assumptions for ACEs are still relatively strong, especially for Assumptions 
A6 and A7. Assumptions A6 and A7 are used to estimate the principal stratum. In commonly used 
sensitivity analyses for imputing the unobserved outcome, some sensitivity parameters (often 
conservative) are used to understand the robustness of the results; however, for estimating the principal 
stratum, it is difficult to say what is “conservative”. Further research is required to better understand this 
assumption and some related sensitivity analyses. We expect the research in this area will continue to 
evolve, and more robust estimators may be available in the future.  
In the example presented in this article, we found there were some differences in the baseline 
characteristics between adherers and non-adherers, but there was little difference in baseline 
characteristics between treatments for the observed adherers. In addition, the estimates for the treatment 
difference for the principal stratum for patients who could adhere to both treatments did not seem very 
different from the estimates for the estimand for all randomized patients based on hypothetical strategies. 
This is not surprising for several reasons. 
Firstly, both treatments were the same class of drugs (daily basal insulin) and the expected treatment 
difference in the primary outcome of HbA1c was small (noting the primary objective of the IMAGINE-3 
study was for non-inferiority). BIL was the first insulin showing greater reduction in HbA1c compared to 
another basal insulin, although the difference was only 0.2 to 0.3%. In addition, the lack of difference in 
the proportions of the first ICE due to LoE also suggested the difference in efficacy would likely to be 
small. 
Secondly, the majority of AEs were not related to the study medication and were probably not related to 
efficacy measurements, as in most clinical trials. 
Thirdly, the difference in the proportion of patients with the first ICE due to AE was primarily due to 
injection site reaction, which was treatment dependent, but was considered unlikely to be related to 
efficacy from a medical perspective. 
Fourthly, the majority of patients were adherent to the assigned treatment, so the difference between the 
adherers’ estimand and an estimand based on the hypothetical strategies was expected to be small.  
In summary, lack of dramatic differences between different estimates, between treatments for baseline 
characteristics for adherers, and between adherers and non-adherers were not a sign of failure of ACEs, 
although failing on some assumptions might also result in indifferent outcomes. Indeed, unless there is a 
dramatic difference in ICEs that are correlated with efficacy, we expect similar “lack of difference” 
results will be present for the majority of clinical trials. In the simulation for the evaluation of the 
performance of ACEs [6], the simulation setting mimics the HbA1c change in real placebo-compared 
clinical trials. The probability of ICEs was modelled by baseline covariates and post-baseline intermediate 
efficacy measurements. Although there were differences in the proportion of patients with ICEs between 
treatments, the differences between estimates for the treatment difference for S**, S*+, and S++ were less 
than 0.2%.  
In conclusion, the trade-offs between the degree of efficacy conferred when taking a medication as 
prescribed and the occurrence of ICEs due to AE and LoE are essential and the tripartite estimands 
provide an opportunity for a more coherent evaluation of efficacy and safety, compared to the single 
estimand approach most often based on ITT currently in practice. ACEs, with the most reasonable 
assumptions among all existing estimators for estimands for principal stratum, can be used to estimate 
Estimand 3 of the treatment difference for adherers. Challenges remain, however, for the estimation of the 
estimand for adherers, including the assumptions and sensitivity analyses.  
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Appendix  
 
Table A.1. Baseline characteristics by reason for disposition status 
Variable 
DC due to AE 
N=94 
DC due to LoE 
N=128 
DC due to 
Admin 
N=120 
DC due to Any 
Reason 
N=235† 
Adherers 
N=877 
P-value‡ 
Age 40.55±13.55 41.83±13.78 38.80±14.48 39.70±13.90 42.48±13.15 0.004 
BMI (kg/m2) 25.92±3.51 26.85±3.70 26.34±4.54 26.23±4.08 26.56±3.91 0.247 
Body weight (kg) 74.75±14.31 82.00±15.10 76.66±14.48 76.60±14.73 79.99±14.94 0.002 
Diabetes duration (years) 19.43±13.00 25.98±17.19 17.36±12.01 18.83±12.72 20.01±12.49 0.201 
Baseline HbA1c (%) 7.84±1.03 7.75±1.36 8.17±1.24 8.01±1.19 7.82±1.12 0.028 
HbA1c (%) right before DC 7.50±1.09 8.08±1.36 7.75±1.15 7.68±1.17 7.43±1.01 0.003 
LDL-C (mg/dL) 97.84±27.30 98.51±32.99 101.17±34.36 100.22±31.71 99.49±29.58 0.739 
Triglycerides (mg/dL) 94.40±75.54 93.89±54.37 99.77±85.09 96.71±78.74 85.17±59.17 0.037 
Total cholesterol (mg/dL) 182.34±32.46 182.95±36.28 183.19±38.07 183.44±35.98 179.33±34.25 0.106 
HDL-C (mg/dL) 65.89±15.94 65.67±16.12 62.50±17.32 64.21±16.80 62.94±17.26 0.313 
FSG (mg/dL) 176.41±77.88 170.21±66.15 170.49±82.95 172.86±79.80 171.73±78.02 0.844 
ALT (U/L) 21.74±16.12 23.07±11.97 21.69±13.25 21.99±14.44 21.98±10.91 0.993 
AST (U/L) 23.43±11.35 25.38±13.13 23.12±10.64 23.60±11.31 22.99±9.76 0.452 
Total bilirubin (umol/L) 8.78±4.97 9.48±5.33 8.73±4.84 8.92±4.99 9.91±5.23 0.009 
Male 41 (43.6) 17 (58.6) 64 (53.3) 119 (50.6) 559 (63.7) <.001 
Region      0.018 
      European Union 26 (27.7) 2 (6.9) 31 (25.8) 59 (25.1) 302 (34.4)  
      North America 51 (54.3) 22 (75.9) 76 (63.3) 143 (60.9) 479 (54.6)  
      Other 17 (18.1) 5 (17.2) 13 (10.8) 33 (14.0)  96 (10.9)  
Hypertension 31 (33.0) 10 (34.5) 42 (35.0) 79 (33.6) 325 (37.1) 0.36 
Lipid lowering medication 29 (30.9) 8 (27.6) 39 (32.5) 72 (30.6) 319 (36.4) 0.107 
Statin 26 (27.7) 7 (24.1) 30 (25.0) 60 (25.5) 296 (33.8) 0.018 
Smoking      0.006 
      Current user 24 (25.5) 5 (17.2) 25 (20.8) 53 (22.6) 127 (14.5)  
      Never used 58 (61.7) 19 (65.5) 74 (61.7) 147 (62.6) 570 (65.0)  
      Past user 12 (12.8) 5 (17.2) 21 (17.5) 35 (14.9) 180 (20.5)  
eGFR      0.389 
      ≥ 30 to < 60 8 (8.5) 1 (3.4) 9 (7.5) 17 (7.2)  68 (7.8)  
      ≥ 60 to < 90 50 (53.2) 16 (55.2) 49 (40.8) 111 (47.2) 454 (51.8)  
      ≥ 90 36 (38.3) 12 (41.4) 62 (51.7) 107 (45.5) 355 (40.5)  
Prior MI/CR/CABG 4 (4.3) 2 (6.9) 0 (0.0) 4 (1.7)  20 (2.3) 0.801 
Mean±SD for continuous variables and the number (%) for categorical variables. Abbreviations: Admin, administration; AE, adverse event; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CABG, coronary artery bypass grafting; CR, cardiac rehabilitation; DC, 
discontinuation; eGFR, estimated glomerular filtration rate; FSG, fasting serum glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; 
LDL-C, low-density lipoprotein cholesterol; LoE, lack of efficacy; MI, myocardial infarction. 
†Several patients discontinued due to the reasons of both of AE and LoE. 
‡The comparison of adherers versus patient who discontinued their study medication using p-values is meant to be a descriptive in measuring how disparate or 
similar the two groups of patients are. These p-values should not be interpreted as leading to inferential conclusion relating to multiple hypothesis tests. 
 
 
  
Table A.2. Baseline characteristics for adherers by treatment 
  
Variable GL (N=368) BIL (N=509) 
Age 43.10±12.84 42.04±13.36 
BMI (kg/m2) 26.73±4.00 26.45±3.85 
Body weight (kg) 80.31±15.50 79.75±14.52 
Diabetes duration (years) 20.64±12.65 19.55±12.36 
Baseline HbA1c (%) 7.79±1.07 7.85±1.15 
HbA1c (%) right before DC 7.55±1.04 7.34±0.98 
LDL-C (mg/dL) 99.92±29.32 99.17±29.79 
Triglycerides (mg/dL) 82.60±45.17 87.02±67.48 
Total cholesterol (mg/dL) 179.48±33.59 179.23±34.76 
HDL-C (mg/dL) 63.03±16.52 62.87±17.79 
FSG (mg/dL) 168.97±76.24 173.72±79.30 
ALT (U/L) 21.48±9.29 22.34±11.94 
AST (U/L) 23.01±9.07 22.98±10.24 
Total bilirubin (umol/L) 9.96±5.27 9.87±5.20 
Male 233 (63.3) 326 (64.0) 
Region   
      European Union 133 (36.1) 169 (33.2) 
      North America 194 (52.7) 285 (56.0) 
      Other  41 (11.1)  55 (10.8) 
Hypertension 144 (39.1) 181 (35.6) 
Lipid lowering medication 137 (37.2) 182 (35.8) 
Statin 127 (34.5) 169 (33.2) 
Smoking   
      Current user  58 (15.8)  69 (13.6) 
      Never used 235 (63.9) 335 (65.8) 
      Past user  75 (20.4) 105 (20.6) 
eGFR   
      ≥ 30 to < 60  22  (6.0)  46  (9.0) 
      ≥ 60 to < 90 204 (55.4) 250 (49.1) 
      ≥ 90 142 (38.6) 213 (41.8) 
Prior MI/CR/CABG 9  (2.4)  11  (2.2) 
Mean±SD for continuous variables and the number (%) for categorical variables. Abbreviations: ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; BIL, basal insulin peglispro; BMI, body mass index; CABG, 
coronary artery bypass grafting; CR, cardiac rehabilitation; DC, discontinuation; eGFR, estimated glomerular 
filtration rate; FSG, fasting serum glucose; GL, basal insulin glargine; HbA1c, hemoglobin A1c; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction. 
 
  
Figure A.1. The relative importance of baseline covariates and treatment on adherence based on gradient boosting 
machine model (p-value was calculated based on a randomized permutation test).  
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CABG, 
coronary artery bypass grafting; CR, cardiac rehabilitation; eGFR, estimated glomerular filtration rate; FSG, fasting 
serum glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; MI, myocardial infarction. 
 
 
 
